Clene's CNM-Au8 Trials Show Promise for ALS and MS Treatment
Clene's CNM-Au8 trials for ALS and MS treatment show promise for improving patient outcomes. The innovative approach could have a significant impact on the therapeutic market.
This news matters because Clene's innovative approach to treating ALS and MS could significantly improve outcomes for patients suffering from these neurodegenerative diseases. The potential impact on the therapeutic market for ALS and MS could provide new hope for patients and their families.
